Several retrospective studies suggested that patients harboring an astrocytoma benefit the most from aggressive tumor removal compared to other low-grade appearing tumors, such as radiologically low-grade appearing IDH-wildtype tumors or oligodendrogliomas [2-4]. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).